<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MARGESIC- butalbital, acetaminophen and caffeine capsule </strong><br>Marnel Pharmaceuticals, LLC<br></p></div>
<h1><span class="Bold"></span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_49fc2d46-d19a-43f4-b9c8-ba2be7593d39"></a><a name="section-1"></a><p></p>
<h1>WARNING</h1>
<div class="Warning">
<a name="i4i_table_id_563a66ef-7e3f-4e7f-82f0-318013cb86d0"></a><a name="section-1.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">HEPATOTOXICITY</span></p>
<p>ACETAMINOPHEN HAS BEEN ASSOCIATED WITH CASES OF <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">ACUTE LIVER FAILURE</span>, AT TIMES RESULTING IN LIVER TRANSPLANT AND <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. MOST OF THE CASES OF <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> ARE ASSOCIATED WITH THE USE OF ACETAMINOPHEN AT DOSES THAT EXCEED 4000 MILLIGRAMS PER DAY, AND OFTEN INVOLVE MORE THAN ONE ACETAMINOPHEN-CONTAINING PRODUCT.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5f813b4f-efd5-4f49-a806-a9441dc67a2d"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Butalbital, acetaminophen and caffeine are supplied in capsule form for oral administration.</p>
<p>Each capsule contains:</p>
<p>Butalbital ................... 50 mg</p>
<p><span class="Bold">Warning: </span>May be habit-forming.</p>
<p>Acetaminophen ........ 325 mg</p>
<p>Caffeine ...................... 40 mg</p>
<p>In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate. microcrystalline cellulose with capsule shell composed of gelatin (silicon dioxide and sodium lauryl sulfate are added as manufacturing aides) and titanium dioxide. Imprinting ink composed of n-butyl alcohol, pharmaceutical glaze modified in SD-45, propylene glycol, SDA-3A alcohol, titanium dioxide, D&amp;C Yellow No. 10 Aluminum Lake and FD&amp;C Blue No. 1 Aluminum Lake.</p>
<p>Butalbital (5-allyl-5-isobutylbarbituric acid), a slightly bitter, white, odorless, crystalline powder, is a short to intermediate-acting barbiturate. It has the following structural formula:</p>
<div class="Figure">
<a name="id277"></a><img alt="butalbital chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=338b9f27-7097-4675-9ec5-e1eea6898cd5&amp;name=45e5829d-8800-4cff-8c5b-c881c2a9db39-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">11</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">3</span><span class="Sub"> </span> MW = 224.26 </p>
</div>
<p>Acetaminophen (4'-hydroxyacetanilide), a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:</p>
<div class="Figure">
<a name="id286"></a><img alt="acetaminophen chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=338b9f27-7097-4675-9ec5-e1eea6898cd5&amp;name=45e5829d-8800-4cff-8c5b-c881c2a9db39-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2</span> MW = 151.16 </p>
</div>
<p>Caffeine (1,3,7-trimethylxanthine), a bitter, white powder or white-glistening needles, is a central nervous system stimulant. It has the following structural formula:</p>
<div class="Figure">
<a name="id293"></a><img alt="caffeine chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=338b9f27-7097-4675-9ec5-e1eea6898cd5&amp;name=45e5829d-8800-4cff-8c5b-c881c2a9db39-03.jpg"><p class="MultiMediaCaption">C<span class="Sub">8</span>H<span class="Sub">10</span>N<span class="Sub">4</span>O<span class="Sub">2</span> MW = 194.19 </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_4115d4cb-dbbe-4f3a-a8ff-9a71b9ef9ad2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">This combination drug product is intended as a treatment for <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span>.</p>
<p>It consists of a fixed combination of butalbital, acetaminophen and caffeine. The role each component plays in the relief of the complex of symptoms known as <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> is not completely understood.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d0dbf268-36c5-4d0f-96fc-0ae4eaaa0a70"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The behavior of the individual components is described below.</p>
<p><span class="Underline">Butalbital</span>:  Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.</p>
<p>Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.</p>
<p>The <span class="Italics">in vitro </span>plasma protein binding of butalbital is 45% over the concentration range of 0.5 to 20 mcg/mL. This <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> within the range of plasma protein binding (20% to 45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity, indicating that there is no preferential distribution of butalbital into either plasma or blood cells (See <a href="#i4i_overdosage_id_be0161dc-ae41-42a6-b3a5-c4a6ee4ff619">OVERDOSAGE</a> for toxicity information.)</p>
<p><span class="Underline">Acetaminophen</span>:  Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug. (See <a href="#i4i_overdosage_id_be0161dc-ae41-42a6-b3a5-c4a6ee4ff619">OVERDOSAGE</a> for toxicity information.)</p>
<p><span class="Underline">Caffeine</span>:  Like most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk.</p>
<p>Caffeine is cleared through metabolism and excretion in the urine. The plasma half-life is about 3 hours. Hepatic biotransformation prior to excretion, results in about equal amounts of 1-methylxanthine and 1-methyluric acid. Of the 70% of the dose that is recovered in the urine, only 3% is unchanged drug. (See <a href="#i4i_overdosage_id_be0161dc-ae41-42a6-b3a5-c4a6ee4ff619">OVERDOSAGE</a> for toxicity information.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0b959853-d1a3-4862-ba60-3e8bbd282972"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Margesic Capsules (butalbital, acetaminophen and caffeine capsules USP 50 mg/325 mg/40 mg) are indicated for the relief of the symptom complex of <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> (or muscle contraction) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_ea4b8bb3-43e2-4725-8067-7b6aa6f25d95"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product is contraindicated under the following conditions:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or intolerance to any component of this product.</dd>
<dt>•</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_84300a20-49cd-40e1-9fc9-8b3cbb5981cc"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca26c440-6bc4-48dd-b59b-47507a39e1e2"></a><a name="section-6.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</p>
<p>Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d706db3-4252-4df5-b515-1d965b0d1794"></a><a name="section-6.2"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Rarely, acetaminophen may cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal.  Patients should be informed about the signs of serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1396c268-0342-454b-9d47-3e9f369eb8b5"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue Margesic Capsules immediately and seek medical care if they experience these symptoms. Do not prescribe Margesic Capsules for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cb296353-bec1-4537-bd68-f2213940c586"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_07605628-4c93-4f9a-affe-663358e06f00"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Margesic Capsules should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1aa95992-8db6-420b-9d57-33f420200f19"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<dl>
<dt>•</dt>
<dd>Do not take Margesic Capsules if you are allergic to any of its ingredients.</dd>
<dt>•</dt>
<dd>If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, stop taking Margesic Capsules and contact your healthcare provider immediately.</dd>
<dt>•</dt>
<dd>Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.</dd>
</dl>
<p class="First">This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.</p>
<p>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, when taken with this combination product, and should be avoided.</p>
<p>Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_4b274eea-8c18-4552-99cf-8321bf0331b6"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_c771e07b-34af-4c82-8159-64677792eab7"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.</p>
<p>Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_8fe6a6fb-dc07-45d2-88f8-bbca0b53c6c9"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_1a94e9ed-e340-4572-9cd9-778797f60f4f"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_13e35905-e95d-402c-8c6e-469e10a0609a"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_b4d7d87e-4993-4ecd-8b7b-30f07fbccdb2"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_aeac3867-79eb-4990-8dac-8fcb1dd99f8b"></a><a name="section-7.7.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with this combination product. It is also not known whether butalbital, acetaminophen and caffeine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_99be48ae-5162-4ae5-8b5e-5c6db240a98b"></a><a name="section-7.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal seizures</span> were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant’s serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or other withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_c5e25286-312a-4dc5-82be-f76f873b5bc8"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caffeine, barbiturates and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from butalbital, acetaminophen and caffeine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_6326ce5d-19c3-4278-98b2-0ae09392b9ee"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7fe1df2b-b9b1-4f98-8e26-0dcc7a40f879"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of butalbital, acetaminophen and caffeine capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>Butalbital is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_63303be4-0dd0-4ae7-a3c7-c0907ea1a466"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb0c976f-57c1-4137-a507-8d1b2401d5b5"></a><a name="section-8.1"></a><p></p>
<h2>Frequently Observed</h2>
<p class="First">The most frequently reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and intoxicated feeling.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb9140b6-306e-4672-a24e-be0da4b287e1"></a><a name="section-8.2"></a><p></p>
<h2>Infrequently Observed</h2>
<p class="First">All adverse events tabulated below are classified as infrequent.</p>
<p><span class="Italics">Central Nervous Systems: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, shaky feeling, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, heavy eyelids, high energy, hot spells, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.</p>
<p><span class="Italics">Autonomic Nervous System: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Italics">Gastrointestinal: </span>difficulty swallowing, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>.</p>
<p><span class="Italics">Genitourinary: </span><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p><span class="Italics">Miscellaneous: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </p>
<p>Several cases of dermatological reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, have been reported.</p>
<p><span class="Bold">The following adverse drug events may be borne in mind as potential effects of the components of this product. Potential effects of high dosage are listed in the OVERDOSAGE section.</span></p>
<p><span class="Italics">Acetaminophen: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p><span class="Italics">Caffeine: </span>cardiac stimulation, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_1fc1c9a1-9fd5-4ef4-8ef0-2c7ae4425c74"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_805feb0e-eece-4a07-af96-07051c946c21"></a><a name="section-9.1"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First"><span class="Underline">Butalbital</span>: <span class="Italics">Barbiturates may be habit-forming</span>: Tolerance, psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient’s regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_be0161dc-ae41-42a6-b3a5-c4a6ee4ff619"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage of butalbital, acetaminophen and caffeine, toxicity may result from the barbiturate or the acetaminophen. Toxicity due to caffeine is less likely, due to the relatively small amounts in this formulation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5278d66-494f-4c28-91af-0edbc4fd1f1b"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Bold"><span class="Italics">barbiturate</span></span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; and <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>.</p>
<p>In <span class="Bold"><span class="Italics">acetaminophen</span></span> overdosage: dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. Renal tubular necroses, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
<p>Acute <span class="Bold"><span class="Italics">caffeine</span></span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may cause <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_178a5744-f397-4826-b20e-a9985293be94"></a><a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with this combination product is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption.</p>
<p>Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered</p>
<p>Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation.  Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading.  To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected.  Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.  Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b51e9837-55da-42af-b8bb-a33b2ac8d086"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One or two capsules every four hours. Total daily dosage should not exceed 6 capsules. </p>
<p>Extended and repeated use of this product is not recommended because of the potential for physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_2efd410a-a14c-4ab6-ab33-34c4d7a9b5e9"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Margesic Capsules containing butalbital 50 mg <span class="Bold">(Warning: May be habit-forming)</span>, acetaminophen 325 mg and caffeine 40 mg, are supplied in bottles of 100 capsules, NDC 0682-0804-01. Capsules are opaque white, body and cap, and are imprinted "MARGESIC/MARNEL" in kelly green ink.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_f8498347-e56e-4cdd-9861-1c0e4adf2216"></a><a name="section-12.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_929ab645-ad9d-4ed8-8361-d20442eb73dd"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Manufactured for:</p>
<p><span class="Bold">MARNEL PHARMACEUTICALS, LLC</span></p>
<p>Lafayette, LA 70506</p>
<p>Manufactured by:</p>
<p><span class="Bold">MIKART, INC.</span></p>
<p>Atlanta, GA 30318</p>
<p>Code 785G00</p>
<p>Rev. 04/15</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7568e322-b14f-4e43-ad68-7888efce7af5"></a><a name="section-14"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id6010243"></a><img alt="container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=338b9f27-7097-4675-9ec5-e1eea6898cd5&amp;name=45e5829d-8800-4cff-8c5b-c881c2a9db39-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MARGESIC 		
					</strong><br><span class="contentTableReg">butalbital, acetaminophen and caffeine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0682-0804</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUTALBITAL</strong> (BUTALBITAL) </td>
<td class="formItem">BUTALBITAL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">325 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MARGESIC;MARNEL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0682-0804-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA089007</td>
<td class="formItem">06/01/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Marnel Pharmaceuticals, LLC
							(079582621)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>45e5829d-8800-4cff-8c5b-c881c2a9db39</div>
<div>Set id: 338b9f27-7097-4675-9ec5-e1eea6898cd5</div>
<div>Version: 3</div>
<div>Effective Time: 20150427</div>
</div>
</div> <div class="DistributorName">Marnel Pharmaceuticals, LLC</div></p>
</body></html>
